Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 170

1.

Disease Pathways and Mechanisms of Potential Drug Targets.

Ghany MG, Block TM.

Clin Liver Dis (Hoboken). 2018 Aug 22;12(1):12-18. doi: 10.1002/cld.735. eCollection 2018 Jul. Review. No abstract available.

2.

Correction: Application of the Doylestown algorithm for the early detection of hepatocellular carcinoma.

Mehta AS, Lau DT, Wang M, Aslam A, Nasir B, Javaid A, Poongkunran M, Block TM.

PLoS One. 2018 Oct 29;13(10):e0206835. doi: 10.1371/journal.pone.0206835. eCollection 2018.

3.

Application of the Doylestown algorithm for the early detection of hepatocellular carcinoma.

Mehta AS, Lau DT, Wang M, Aslam A, Nasir B, Javaid A, Poongkunran M, Block TM.

PLoS One. 2018 Aug 31;13(8):e0203149. doi: 10.1371/journal.pone.0203149. eCollection 2018. Erratum in: PLoS One. 2018 Oct 29;13(10):e0206835.

4.

Host functions used by hepatitis B virus to complete its life cycle: Implications for developing host-targeting agents to treat chronic hepatitis B.

Mitra B, Thapa RJ, Guo H, Block TM.

Antiviral Res. 2018 Oct;158:185-198. doi: 10.1016/j.antiviral.2018.08.014. Epub 2018 Aug 24. Review.

5.

Do hepatitis B virus surface antigens have any role in viral carcinogenesis?

Guo JT, Block TM.

Hepatology. 2018 Sep;68(3):801-803. doi: 10.1002/hep.29886. Epub 2018 Jul 16. No abstract available.

PMID:
29572901
6.

Enhancing the antiviral potency of ER α-glucosidase inhibitor IHVR-19029 against hemorrhagic fever viruses in vitro and in vivo.

Ma J, Zhang X, Soloveva V, Warren T, Guo F, Wu S, Lu H, Guo J, Su Q, Shen H, Solon E, Comunale MA, Mehta A, Guo JT, Bavari S, Du Y, Block TM, Chang J.

Antiviral Res. 2018 Feb;150:112-122. doi: 10.1016/j.antiviral.2017.12.008. Epub 2017 Dec 15.

7.

Research priorities for the discovery of a cure for chronic hepatitis B: Report of a workshop.

Block TM, Alter H, Brown N, Brownstein A, Brosgart C, Chang KM, Chen PJ, Cohen C, El-Serag H, Feld J, Gish R, Glenn J, Greten TF, Guo JT, Hoshida Y, Kowdley KV, Li W, Lok AS, McMahon B, Mehta A, Perrillo R, Rice CM, Rinaudo J, Schinazi RF, Shetty K.

Antiviral Res. 2018 Feb;150:93-100. doi: 10.1016/j.antiviral.2017.12.006. Epub 2017 Dec 14.

8.

Discovery and Mechanistic Study of Benzamide Derivatives That Modulate Hepatitis B Virus Capsid Assembly.

Wu S, Zhao Q, Zhang P, Kulp J, Hu L, Hwang N, Zhang J, Block TM, Xu X, Du Y, Chang J, Guo JT.

J Virol. 2017 Jul 27;91(16). pii: e00519-17. doi: 10.1128/JVI.00519-17. Print 2017 Aug 15.

9.

Identification of fucosylated Fetuin-A as a potential biomarker for cholangiocarcinoma.

Betesh L, Comunale MA, Wang M, Liang H, Hafner J, Karabudak A, Giama NH, Moser CD, Miyoshi E, Roberts LR, Block TM, Mehta A.

Proteomics Clin Appl. 2017 Sep;11(9-10). doi: 10.1002/prca.201600141. Epub 2017 Jul 10.

10.

Interferon-inducible ribonuclease ISG20 inhibits hepatitis B virus replication through directly binding to the epsilon stem-loop structure of viral RNA.

Liu Y, Nie H, Mao R, Mitra B, Cai D, Yan R, Guo JT, Block TM, Mechti N, Guo H.

PLoS Pathog. 2017 Apr 11;13(4):e1006296. doi: 10.1371/journal.ppat.1006296. eCollection 2017 Apr.

11.

Use of Current and New Endpoints in the Evaluation of Experimental Hepatitis B Therapeutics.

Block TM, Locarnini S, McMahon BJ, Rehermann B, Peters MG.

Clin Infect Dis. 2017 May 1;64(9):1283-1288. doi: 10.1093/cid/cix129. Review.

12.

Ester Prodrugs of IHVR-19029 with Enhanced Oral Exposure and Prevention of Gastrointestinal Glucosidase Interaction.

Ma J, Wu S, Zhang X, Guo F, Yang K, Guo J, Su Q, Lu H, Lam P, Li Y, Yan Z, Kinney W, Guo JT, Block TM, Chang J, Du Y.

ACS Med Chem Lett. 2017 Jan 17;8(2):157-162. doi: 10.1021/acsmedchemlett.6b00332. eCollection 2017 Feb 9.

13.

Evolving New Strategies for the Medical Management of Chronic Hepatitis B Virus Infection.

Block TM, Zhou T, Anbarasan N, Gish R.

Gastroenterol Hepatol (N Y). 2016 Nov;12(11):679-689.

14.

A Novel Benzodiazepine Compound Inhibits Yellow Fever Virus Infection by Specifically Targeting NS4B Protein.

Guo F, Wu S, Julander J, Ma J, Zhang X, Kulp J, Cuconati A, Block TM, Du Y, Guo JT, Chang J.

J Virol. 2016 Nov 14;90(23):10774-10788. doi: 10.1128/JVI.01253-16. Print 2016 Dec 1.

15.

A historical perspective on the discovery and elucidation of the hepatitis B virus.

Block TM, Alter HJ, London WT, Bray M.

Antiviral Res. 2016 Jul;131:109-23. doi: 10.1016/j.antiviral.2016.04.012. Epub 2016 Apr 20.

PMID:
27107897
16.

The Doylestown Algorithm: A Test to Improve the Performance of AFP in the Detection of Hepatocellular Carcinoma.

Wang M, Devarajan K, Singal AG, Marrero JA, Dai J, Feng Z, Rinaudo JA, Srivastava S, Evans A, Hann HW, Lai Y, Yang H, Block TM, Mehta A.

Cancer Prev Res (Phila). 2016 Feb;9(2):172-9. doi: 10.1158/1940-6207.CAPR-15-0186. Epub 2015 Dec 28.

17.

Geneticin Stabilizes the Open Conformation of the 5' Region of Hepatitis C Virus RNA and Inhibits Viral Replication.

Ariza-Mateos A, Díaz-Toledano R, Block TM, Prieto-Vega S, Birk A, Gómez J.

Antimicrob Agents Chemother. 2015 Nov 30;60(2):925-35. doi: 10.1128/AAC.02511-15. Print 2016 Feb.

18.

The Covalently Closed Circular Form of Hepatitis B Virus Genome: Is There Now an End in "Site"?

Block TM, Guo JT.

Gastroenterology. 2016 Jan;150(1):34-6. doi: 10.1053/j.gastro.2015.11.032. Epub 2015 Nov 22. No abstract available.

PMID:
26615119
19.

Data supporting updating estimates of the prevalence of chronic hepatitis B and C in the United States.

Gish RG, Cohen CA, Block JM, Brosgart CL, Block TM, Clary R, Le LT, Ninburg MH, Sandt L, Kowdley KV.

Hepatology. 2015 Nov;62(5):1339-41. doi: 10.1002/hep.28026. Epub 2015 Sep 29. No abstract available.

20.

Present and future therapies of hepatitis B: From discovery to cure.

Liang TJ, Block TM, McMahon BJ, Ghany MG, Urban S, Guo JT, Locarnini S, Zoulim F, Chang KM, Lok AS.

Hepatology. 2015 Dec;62(6):1893-908. doi: 10.1002/hep.28025. Epub 2015 Oct 27. Review.

21.

Chronic hepatitis B: A wave of new therapies on the horizon.

Block TM, Rawat S, Brosgart CL.

Antiviral Res. 2015 Sep;121:69-81. doi: 10.1016/j.antiviral.2015.06.014. Epub 2015 Jun 22. Review.

22.

The Interferon-Inducible Protein Tetherin Inhibits Hepatitis B Virus Virion Secretion.

Yan R, Zhao X, Cai D, Liu Y, Block TM, Guo JT, Guo H.

J Virol. 2015 Sep;89(18):9200-12. doi: 10.1128/JVI.00933-15. Epub 2015 Jun 24.

23.

Comprehensive DNA methylation analysis of hepatitis B virus genome in infected liver tissues.

Jain S, Chang TT, Chen S, Boldbaatar B, Clemens A, Lin SY, Yan R, Hu CT, Guo H, Block TM, Song W, Su YH.

Sci Rep. 2015 May 22;5:10478. doi: 10.1038/srep10478.

24.

STING agonists induce an innate antiviral immune response against hepatitis B virus.

Guo F, Han Y, Zhao X, Wang J, Liu F, Xu C, Wei L, Jiang JD, Block TM, Guo JT, Chang J.

Antimicrob Agents Chemother. 2015 Feb;59(2):1273-81. doi: 10.1128/AAC.04321-14. Epub 2014 Dec 15.

25.

Differential methylation of the promoter and first exon of the RASSF1A gene in hepatocarcinogenesis.

Jain S, Xie L, Boldbaatar B, Lin SY, Hamilton JP, Meltzer SJ, Chen SH, Hu CT, Block TM, Song W, Su YH.

Hepatol Res. 2015 Nov;45(11):1110-23. doi: 10.1111/hepr.12449. Epub 2014 Dec 9.

26.

Inhibition of endoplasmic reticulum-resident glucosidases impairs severe acute respiratory syndrome coronavirus and human coronavirus NL63 spike protein-mediated entry by altering the glycan processing of angiotensin I-converting enzyme 2.

Zhao X, Guo F, Comunale MA, Mehta A, Sehgal M, Jain P, Cuconati A, Lin H, Block TM, Chang J, Guo JT.

Antimicrob Agents Chemother. 2015 Jan;59(1):206-16. doi: 10.1128/AAC.03999-14. Epub 2014 Oct 27.

27.

Viral resistance of MOGS-CDG patients implies a broad-spectrum strategy against acute virus infections.

Chang J, Block TM, Guo JT.

Antivir Ther. 2015;20(3):257-9. doi: 10.3851/IMP2907. Epub 2014 Oct 15.

28.

An interferon-beta promoter reporter assay for high throughput identification of compounds against multiple RNA viruses.

Guo F, Zhao X, Gill T, Zhou Y, Campagna M, Wang L, Liu F, Zhang P, DiPaolo L, Du Y, Xu X, Jiang D, Wei L, Cuconati A, Block TM, Guo JT, Chang J.

Antiviral Res. 2014 Jul;107:56-65. doi: 10.1016/j.antiviral.2014.04.010. Epub 2014 Apr 30.

29.

Interferon induction of IFITM proteins promotes infection by human coronavirus OC43.

Zhao X, Guo F, Liu F, Cuconati A, Chang J, Block TM, Guo JT.

Proc Natl Acad Sci U S A. 2014 May 6;111(18):6756-61. doi: 10.1073/pnas.1320856111. Epub 2014 Apr 21.

30.

A comparison of statistical methods for the detection of hepatocellular carcinoma based on serum biomarkers and clinical variables.

Wang M, Mehta A, Block TM, Marrero J, Di Bisceglie AM, Devarajan K.

BMC Med Genomics. 2013;6 Suppl 3:S9. doi: 10.1186/1755-8794-6-S3-S9. Epub 2013 Nov 11. Erratum in: BMC Med Genomics. 2013;6 Suppl 3:S11.

31.

Improved biomarker performance for the detection of hepatocellular carcinoma by inclusion of clinical parameters.

Wang M, Block TM, Marrero J, Di Bisceglie AM, Devarajan K, Mehta A.

Proceedings (IEEE Int Conf Bioinformatics Biomed). 2012 Dec;2012. doi: 10.1109/BIBM.2012.6392612.

32.

Lectin-reactive anti-α-gal in patients with Crohn's disease: correlation with clinical phenotypes.

Safaie P, Ham M, Kuang P, Mehta AS, Wang M, Cheifetz AS, Robson S, Lau D, Block TM, Moss AC.

Inflamm Bowel Dis. 2013 Dec;19(13):2796-800. doi: 10.1097/01.MIB.0000435437.76741.cb.

33.

Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes.

Liu F, Campagna M, Qi Y, Zhao X, Guo F, Xu C, Li S, Li W, Block TM, Chang J, Guo JT.

PLoS Pathog. 2013 Sep;9(9):e1003613. doi: 10.1371/journal.ppat.1003613. Epub 2013 Sep 12.

34.

Total serum glycan analysis is superior to lectin-FLISA for the early detection of hepatocellular carcinoma.

Comunale MA, Wang M, Anbarasan N, Betesh L, Karabudak A, Moritz E, Devarajan K, Marrero J, Block TM, Mehta A.

Proteomics Clin Appl. 2013 Oct;7(9-10):690-700. doi: 10.1002/prca.201200125. Epub 2013 Sep 13.

35.

Inhibition of hepatitis B virus replication by the host zinc finger antiviral protein.

Mao R, Nie H, Cai D, Zhang J, Liu H, Yan R, Cuconati A, Block TM, Guo JT, Guo H.

PLoS Pathog. 2013;9(7):e1003494. doi: 10.1371/journal.ppat.1003494. Epub 2013 Jul 11.

36.

A southern blot assay for detection of hepatitis B virus covalently closed circular DNA from cell cultures.

Cai D, Nie H, Yan R, Guo JT, Block TM, Guo H.

Methods Mol Biol. 2013;1030:151-61. doi: 10.1007/978-1-62703-484-5_13.

37.

Antiviral therapies targeting host ER alpha-glucosidases: current status and future directions.

Chang J, Block TM, Guo JT.

Antiviral Res. 2013 Sep;99(3):251-60. doi: 10.1016/j.antiviral.2013.06.011. Epub 2013 Jun 29. Review.

PMID:
23816430
38.

Design and synthesis of N-alkyldeoxynojirimycin derivatives with improved metabolic stability as inhibitors of BVDV and Tacaribe virus.

Du Y, Ye H, Guo F, Wang L, Gill T, Khan N, Cuconati A, Guo JT, Block TM, Chang J, Xu X.

Bioorg Med Chem Lett. 2013 Jul 15;23(14):4258-62. doi: 10.1016/j.bmcl.2013.04.052. Epub 2013 May 9.

PMID:
23747225
39.

Small molecule inhibitors of ER α-glucosidases are active against multiple hemorrhagic fever viruses.

Chang J, Warren TK, Zhao X, Gill T, Guo F, Wang L, Comunale MA, Du Y, Alonzi DS, Yu W, Ye H, Liu F, Guo JT, Mehta A, Cuconati A, Butters TD, Bavari S, Xu X, Block TM.

Antiviral Res. 2013 Jun;98(3):432-40. doi: 10.1016/j.antiviral.2013.03.023. Epub 2013 Apr 8.

40.

Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids.

Campagna MR, Liu F, Mao R, Mills C, Cai D, Guo F, Zhao X, Ye H, Cuconati A, Guo H, Chang J, Xu X, Block TM, Guo JT.

J Virol. 2013 Jun;87(12):6931-42. doi: 10.1128/JVI.00582-13. Epub 2013 Apr 10.

41.

N-Alkyldeoxynojirimycin derivatives with novel terminal tertiary amide substitution for treatment of bovine viral diarrhea virus (BVDV), Dengue, and Tacaribe virus infections.

Du Y, Ye H, Gill T, Wang L, Guo F, Cuconati A, Guo JT, Block TM, Chang J, Xu X.

Bioorg Med Chem Lett. 2013 Apr 1;23(7):2172-6. doi: 10.1016/j.bmcl.2013.01.108. Epub 2013 Feb 1.

PMID:
23453839
42.

Chronic hepatitis B: what should be the goal for new therapies?

Block TM, Gish R, Guo H, Mehta A, Cuconati A, Thomas London W, Guo JT.

Antiviral Res. 2013 Apr;98(1):27-34. doi: 10.1016/j.antiviral.2013.01.006. Epub 2013 Feb 4.

43.

Suppression of AKT anti-apoptotic signaling by a novel drug candidate results in growth arrest and apoptosis of hepatocellular carcinoma cells.

Cuconati A, Mills C, Goddard C, Zhang X, Yu W, Guo H, Xu X, Block TM.

PLoS One. 2013;8(1):e54595. doi: 10.1371/journal.pone.0054595. Epub 2013 Jan 23.

44.

Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73.

Liang H, Block TM, Wang M, Nefsky B, Long R, Hafner J, Mehta AS, Marrero J, Gish R, Norton PA.

Cancer Biomark. 2012;11(4):161-71. doi: 10.3233/CBM-2012-00276.

45.

The innate immune response to hepatitis B virus infection: implications for pathogenesis and therapy.

Chang J, Block TM, Guo JT.

Antiviral Res. 2012 Dec;96(3):405-13. doi: 10.1016/j.antiviral.2012.10.001. Epub 2012 Oct 13. Review.

PMID:
23072881
46.

RO 90-7501 enhances TLR3 and RLR agonist induced antiviral response.

Guo F, Mead J, Aliya N, Wang L, Cuconati A, Wei L, Li K, Block TM, Guo JT, Chang J.

PLoS One. 2012;7(10):e42583. doi: 10.1371/journal.pone.0042583. Epub 2012 Oct 3.

47.

Chronic HBV infection outside treatment guidelines: is treatment needed?

Evans AA, London WT, Gish RG, Cohen C, Block TM.

Antivir Ther. 2013;18(2):229-35. doi: 10.3851/IMP2325. Epub 2012 Aug 23.

PMID:
22914436
48.

Characterization of the host factors required for hepadnavirus covalently closed circular (ccc) DNA formation.

Guo H, Xu C, Zhou T, Block TM, Guo JT.

PLoS One. 2012;7(8):e43270. doi: 10.1371/journal.pone.0043270. Epub 2012 Aug 13.

49.

Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.

Yu W, Gill T, Wang L, Du Y, Ye H, Qu X, Guo JT, Cuconati A, Zhao K, Block TM, Xu X, Chang J.

J Med Chem. 2012 Jul 12;55(13):6061-75. doi: 10.1021/jm300171v. Epub 2012 Jun 29.

50.

Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation.

Cai D, Mills C, Yu W, Yan R, Aldrich CE, Saputelli JR, Mason WS, Xu X, Guo JT, Block TM, Cuconati A, Guo H.

Antimicrob Agents Chemother. 2012 Aug;56(8):4277-88. doi: 10.1128/AAC.00473-12. Epub 2012 May 29.

Supplemental Content

Loading ...
Support Center